New combo aims to shrink spleen and boost transplant success in myelofibrosis
NCT ID NCT06345495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving high-dose ruxolitinib and busulfan before a stem cell transplant can reduce spleen size and help the transplant work better in people with myelofibrosis. About 30 adults aged 18 to 75 with an enlarged spleen and a matched donor will take part. The main goal is to check safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- Can a new pill tame myelofibrosis?
- MRI as a window into bone marrow disease: a new biomarker test?
- Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
- Can a drug free myelofibrosis patients from frequent blood transfusions?
- Heart safety check for new myelofibrosis drug in healthy volunteers